- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07834723
NIV-NAVA in Infants With Severe Bronchiolitis, a Pilot Multicenter Randomized Controlled Trial (NAVIGATE)
Non-invasive Ventilation With NAVA in Infants With Severe Bronchiolitis. A Multicenter Pilot Open Label Pragmatic Randomized Controlled Trial (NAVIGATE Trial)
Severe bronchiolitis is a common lung infection in babies that can cause serious breathing problems and often leads to hospitalization in pediatric intensive care units (PICUs). Many infants need special breathing support, usually through non-invasive methods like high-flow oxygen or continuous airway pressure. However, these methods don't always work, and about one in four infants end up needing a breathing tube (intubation), which comes with more risks and a longer recovery.
A newer breathing support method called NIV-NAVA (non-invasive ventilation with neurally adjusted ventilatory assist) may help. It uses signals from the baby's diaphragm to adjust the support in real-time, making breathing easier and possibly reducing the need for intubation. While early results are promising, no high-quality clinical trial has yet tested if NIV-NAVA is better than standard non-invasive support.
This study is a pilot trial - a small-scale version of a larger future study - happening in four PICUs across Canada. It will include 90 babies under 2 years old with severe bronchiolitis who need more support than standard methods provide. Half will receive NIV-NAVA, and half will receive the usual care.
The main goal of this pilot is to check if a larger trial is doable: Can we recruit enough babies? Can the PICU teams stick to the treatment plan? Can we collect the right information? The full study will eventually look at whether NIV-NAVA really lowers the number of babies who need intubation and improves recovery.
This research is led by a team of pediatric experts and could pave the way for better care for thousands of infants with severe breathing problems.
연구 개요
상세 설명
Goal(s) / Research Aims The primary objective of this multicenter pilot RCT is to determine the feasibility of a definitive multicenter RCT that will evaluate whether NIV-NAVA is superior to conventional NIV in infants with severe bronchiolitis who are not adequately supported by HFNC or CPAP. The primary hypothesis is that the pilot RCT will confirm the feasibility of the final trial.
Methods / Approaches This is an investigator-led, multicenter, randomized, controlled, open-label, pragmatic pilot trial conducted in four Canadian pediatric intensive care units (PICUs) with varying levels of experience with NIV-NAVA, supported by the Canadian Critical Care Trials Group (CCCTG).
Ninety infants younger than 2 years old who are admitted to the PICU with a clinical diagnosis of bronchiolitis, who require NIV support greater than CPAP/HFNC, and who have no exclusion criteria will be randomized 1:1 between NIV-NAVA and conventional NIV management.
The pilot trial's feasibility outcomes are the recruitment rate (the primary outcome), adherence to the intervention, and completion of the definitive trial's outcome measures. The primary outcome of the future definitive RCT is the intubation rate. Secondary outcomes will include respiratory distress evolution, comfort, duration of ventilatory support, PICU and hospital length of stay, nutrition and sedation, complication rates, post-PICU functional outcomes, carbon footprint, and cost-effectiveness analysis.
Expertise. An experienced, multidisciplinary team of senior, mid, and early career clinician scientists with unique expertise in pediatric NIV, trial methodology, pediatric respirology, and PICU research is leading this project.
Expected Outcomes. We expect this pilot trial to confirm the feasibility of a definitive trial on NIV-NAVA in severe bronchiolitis. As the first RCT in this understudied field, it will provide much-needed evidence on the most effective strategy for reducing intubation rates in infants with severe bronchiolitis.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Guillaume Emeriaud, MD PhD
- 전화번호: 5143454708
- 이메일: guillaume.emeriaud@umontreal.ca
연구 연락처 백업
- 이름: Lucy Clayton, MSc
- 이메일: lucy.clayton.hsj@ssss.gouv.qc.ca
연구 장소
-
-
Alberta
-
Calgary, Alberta, 캐나다
- Alberta Children's Hospital
-
연락하다:
- Laurie Lee, NPS PhD
- 전화번호: 4032206546
- 이메일: laurie.lee@ucalgary.ca
-
-
Ontario
-
Ottawa, Ontario, 캐나다
- CHEO
-
연락하다:
- Dayre McNally, MD
- 전화번호: 6137377600
- 이메일: dmcnally@cheo.on.ca
-
-
Quebec
-
Montreal, Quebec, 캐나다
- Montreal Children's Hospital
-
연락하다:
- Patricia Fontela, MD PhD
- 전화번호: 22855 5144124400
- 이메일: patricia.fontela.med@ssss.gouv.qc.ca
-
Montreal, Quebec, 캐나다
- CHU Sainte Justine
-
연락하다:
- Guillaume Emeriaud, MD PhD
- 전화번호: 5143454708
- 이메일: guillaume.emeriaud@umontreal.ca
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Infants younger than 2 years old
- admitted to the PICU (or managed by the PICU team while awaiting PICU admission)
- with a clinical diagnosis of bronchiolitis according to the treating team
- requiring NIV support higher than CPAP/HFNC according to the treating team, a criteria present for less than 8 hours.
Exclusion Criteria:
- imminent intubation criteria
- refusal by the physician in charge
- chronic home ventilation
- hemodynamic instability requiring vasopressors
- contraindication to NIV or to gastric tube insertion
- patients in whom a limitation of life-support treatment is considered
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: NIV-NAVA arm
Installation of an Edi catheter. Ventilation with NIV-NAVA as long as a bi-level NIV support is needed. |
Non-invasive support using NAVA technology |
|
간섭 없음: Control arm (usual care)
Ventilation according to the clinical team. No NAVA ventilation allowed. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recruitment rate
기간: from initiation to the end of the 6-month study enrolment period
|
% of eligible patients (identified by screening) who are included in the study at each site and overall |
from initiation to the end of the 6-month study enrolment period
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
adherence to the intervention
기간: during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
In the NAVA arm : % of patients who receive at least 2 hours of NIV-NAVA support, within 2 hours after randomization. In control arm: absence of NAVA use |
during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
|
completion of the definitive trial outcomes
기간: from initiation to the end of the 6-month study enrolment period
|
completion of the definitive trial outcomes : measurement of intubation rate, duration of ventilatory support, length of PICU and hospital stays |
from initiation to the end of the 6-month study enrolment period
|
|
Evolution of the respiratory distress mWCAS score
기간: at randomization, and after 2, 6, and 24 hours
|
Evolution of mWCAS |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the respiratory distress ROX-HR score
기간: at randomization, and after 2, 6, and 24 hours
|
Evolution of ROX-HR scores |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the comfort score
기간: at randomization, and after 2, 6, and 24 hours
|
Evolution of the comfort score (FLACC) |
at randomization, and after 2, 6, and 24 hours
|
|
Capacity to assess the evolution at 3 months post PICU
기간: 3 months post PICU discharge
|
Percentage of patients with assessment of PICS-p at 3 months post discharge |
3 months post PICU discharge
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Guillaume Emeriaud, MD PhD, CHU Sainte Justine, Université de Montréal
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- MP-21-2027-10447
- 583747 (기타 보조금/기금 번호: CIHR)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
This is a pilot study. If the pilot shows feasibility of a larger trial with no change in the protocol, we may continue the trial with the same protocol and enroll the subjects from the pilot within the larger trial (Vanguard).
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .